Literature DB >> 15746191

Prolactin and estrogen enhance the activity of activating protein 1 in breast cancer cells: role of extracellularly regulated kinase 1/2-mediated signals to c-fos.

Jennifer H Gutzman1, Sarah E Nikolai, Debra E Rugowski, Jyoti J Watters, Linda A Schuler.   

Abstract

Despite the important roles of both prolactin (PRL) and 17beta-estradiol (E2) in normal mammary development as well as in breast cancer, and coexpression of the estrogen receptor (ER) and PRL receptor in many mammary tumors, the interactions between PRL and E2 in breast cancer have not been well studied. The activating protein 1 (AP-1) transcription factor, a known regulator of processes essential for normal growth and development as well as carcinogenesis, is a potential site for cross-talk between these hormones in breast cancer cells. Here we demonstrate that PRL and E2 cooperatively enhance the activity of AP-1 in MCF-7-derived cells. In addition to the acute PRL-induced ERK1/2 activation, PRL and E2 also individually elicited delayed, sustained rises in levels of phosphorylated p38 and especially ERK1/2. Together, these hormones increased the dynamic phosphorylation of ERK1/2 and c-Fos, and induced c-fos promoter activity. Synergistic activation of the transcription factor, Elk-1, reflected the PRL-E2 interaction at ERK1/2 and is a likely mechanism for activation of the c-fos promoter via the serum response element. The enhanced AP-1 activity resulting from the interaction of these hormones may increase expression of many target genes that are critical for oncogenesis and may contribute to neoplastic progression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15746191      PMCID: PMC1630766          DOI: 10.1210/me.2004-0339

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  87 in total

1.  Identification of an estrogen response element upstream of the human c-fos gene that binds the estrogen receptor and the AP-1 transcription factor.

Authors:  A Weisz; R Rosales
Journal:  Nucleic Acids Res       Date:  1990-09-11       Impact factor: 16.971

Review 2.  The regulation of AP-1 activity by mitogen-activated protein kinases.

Authors:  M Karin
Journal:  J Biol Chem       Date:  1995-07-14       Impact factor: 5.157

3.  A cytoplasmic inhibitor of the JNK signal transduction pathway.

Authors:  M Dickens; J S Rogers; J Cavanagh; A Raitano; Z Xia; J R Halpern; M E Greenberg; C L Sawyers; R J Davis
Journal:  Science       Date:  1997-08-01       Impact factor: 47.728

4.  Plasma membrane estrogen receptors signal to antiapoptosis in breast cancer.

Authors:  M Razandi; A Pedram; E R Levin
Journal:  Mol Endocrinol       Date:  2000-09

Review 5.  The role of prolactin in mammary carcinoma.

Authors:  Charles V Clevenger; Priscilla A Furth; Susan E Hankinson; Linda A Schuler
Journal:  Endocr Rev       Date:  2003-02       Impact factor: 19.871

6.  PRL modulates cell cycle regulators in mammary tumor epithelial cells.

Authors:  Matthew D Schroeder; Jaime Symowicz; Linda A Schuler
Journal:  Mol Endocrinol       Date:  2002-01

7.  FosB is highly expressed in normal mammary epithelia, but down-regulated in poorly differentiated breast carcinomas.

Authors:  Karin Milde-Langosch; Holger Kappes; Sabine Riethdorf; Thomas Löning; Ana-Maria Bamberger
Journal:  Breast Cancer Res Treat       Date:  2003-02       Impact factor: 4.872

8.  The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions.

Authors:  P Webb; P Nguyen; C Valentine; G N Lopez; G R Kwok; E McInerney; B S Katzenellenbogen; E Enmark; J A Gustafsson; S Nilsson; P J Kushner
Journal:  Mol Endocrinol       Date:  1999-10

9.  Multiple kinase cascades mediate prolactin signals to activating protein-1 in breast cancer cells.

Authors:  Jennifer H Gutzman; Debra E Rugowski; Matthew D Schroeder; Jyoti J Watters; Linda A Schuler
Journal:  Mol Endocrinol       Date:  2004-08-19

10.  The association of breast mitogens with mammographic densities.

Authors:  N F Boyd; J Stone; L J Martin; R Jong; E Fishell; M Yaffe; G Hammond; S Minkin
Journal:  Br J Cancer       Date:  2002-10-07       Impact factor: 7.640

View more
  27 in total

Review 1.  Extranuclear signaling by estrogen: role in breast cancer progression and metastasis.

Authors:  V Cortez; M Mann; D W Brann; R K Vadlamudi
Journal:  Minerva Ginecol       Date:  2010-12

2.  Mammary gland zinc metabolism: regulation and dysregulation.

Authors:  Shannon L Kelleher; Young Ah Seo; Veronica Lopez
Journal:  Genes Nutr       Date:  2009-04-02       Impact factor: 5.523

3.  Lactogens and estrogens in breast cancer chemoresistance.

Authors:  Gila Idelman; Eric M Jacobson; Traci R Tuttle; Nira Ben-Jonathan
Journal:  Expert Rev Endocrinol Metab       Date:  2011-05

4.  Breast carcinoma associated with prolactinoma: A case report.

Authors:  Yurong Zheng; Wenju Mo; Yang Yu; Dehong Zou; Xiangming He; Xianghou Xia; Jiejie Hu
Journal:  Cancer Biol Ther       Date:  2017-02-17       Impact factor: 4.742

5.  Prolactin potentiates transforming growth factor alpha induction of mammary neoplasia in transgenic mice.

Authors:  Lisa M Arendt; Teresa A Rose-Hellekant; Eric P Sandgren; Linda A Schuler
Journal:  Am J Pathol       Date:  2006-04       Impact factor: 4.307

6.  Prolactin-growth factor crosstalk reduces mammary estrogen responsiveness despite elevated ERalpha expression.

Authors:  Lisa M Arendt; Tara L Grafwallner-Huseth; Linda A Schuler
Journal:  Am J Pathol       Date:  2009-01-29       Impact factor: 4.307

7.  Prolactin enhances insulin-like growth factor I receptor phosphorylation by decreasing its association with the tyrosine phosphatase SHP-2 in MCF-7 breast cancer cells.

Authors:  Kristopher C Carver; Timothy M Piazza; Linda A Schuler
Journal:  J Biol Chem       Date:  2010-01-15       Impact factor: 5.157

Review 8.  Biological implications of polydimethylsiloxane-based microfluidic cell culture.

Authors:  Keil J Regehr; Maribella Domenech; Justin T Koepsel; Kristopher C Carver; Stephanie J Ellison-Zelski; William L Murphy; Linda A Schuler; Elaine T Alarid; David J Beebe
Journal:  Lab Chip       Date:  2009-06-04       Impact factor: 6.799

9.  ERK activation and cell growth require CaM kinases in MCF-7 breast cancer cells.

Authors:  John M Schmitt; Ellen Abell; Andrea Wagner; Monika A Davare
Journal:  Mol Cell Biochem       Date:  2009-09-18       Impact factor: 3.396

Review 10.  Transgenic models to study actions of prolactin in mammary neoplasia.

Authors:  Lisa M Arendt; Linda A Schuler
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-01-25       Impact factor: 2.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.